Bilfinger awarded €15 million contract by pharmaceutical company GlaxoSmithKline

September 09, 2021

  • Provision of E&I and insulation services at production site in Montrose, Scotland
  • 3-year contract to support projects and maintenance
  • Over 40 Bilfinger employees daily on-site

Bilfinger has secured a ~€15 million (£12.5 million) project and maintenance contract with multinational pharmaceutical company GlaxoSmithKline (GSK) for its production facilities in Montrose, Scotland. The three-year contract, which has an option for a further two-year extension, will be booked under Bilfinger’s Engineering & Maintenance Europe segment and has commenced at the end of July 2021.

"As pharmaceuticals is a strategic growth sector for Bilfinger, we are very pleased to have won GSK as a customer, since they are an international market leader in this industry," says Christina Johansson, interim CEO and CFO of Bilfinger. "With our many years of experience in this industry, highly qualified experts and efficient processes, we are perfectly positioned to deliver everything our customers need from a single source.”

The agreement will see the subsidiary Bilfinger UK provide electrical and instrumentation installation (E&I) as well as access, insulation and painting services. Over 40 Bilfinger employees will work on-site in Montrose, where GSK manufactures active pharmaceutical ingredients for a diverse portfolio of HIV, Respiratory and Corticosteroid medical products.

Bilfinger has been an experienced partner to the pharmaceuticals industry for decades, delivering comprehensive expertise in the production process of pharmaceutical and biotechnological products and providing support throughout the entire lifecycle of a plant.

GlaxoSmithKline plc. is a British multinational pharmaceutical company headquartered in London. GSK is one of the largest healthcare companies worldwide, researching, developing and supplying innovative medicines, vaccines and healthcare products.

Downloads